These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9272352)

  • 1. Diagnostic pertussis serology in the recent clinical efficacy studies of acellular vaccines.
    Hallander HO
    Dev Biol Stand; 1997; 89():205-12. PubMed ID: 9272352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological responses to infection with B. pertussis.
    Giammanco A; Taormina S; Genovese M; Mangiaracina G; Giammanco G; Chiarini A
    Dev Biol Stand; 1997; 89():213-20. PubMed ID: 9272353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
    Storsaeter J; Hallander HO; Gustafsson L; Olin P
    Vaccine; 1998 Dec; 16(20):1907-16. PubMed ID: 9796042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing antibody responses to acellular pertussis vaccines.
    Trollfors B
    Dev Biol Stand; 1997; 89():279-82. PubMed ID: 9272361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
    Cherry JD; Gornbein J; Heininger U; Stehr K
    Vaccine; 1998 Dec; 16(20):1901-6. PubMed ID: 9796041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A consideration of control requirements for acellular pertussis vaccines.
    Corbel MJ; Xing DK
    Dev Biol Stand; 1997; 89():343-7. PubMed ID: 9272369
    [No Abstract]   [Full Text] [Related]  

  • 8. Differences by antigen in seroconversion: sensitivity, specificity and bias in the serological confirmation of pertussis.
    Wassilak SG; Anemona A; Giuliano M; Giammanco A
    Dev Biol Stand; 1997; 89():221-8. PubMed ID: 9272354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines.
    Giuliano M; Mastrantonio P; Giammanco A; Bottone M; Piscitelli A; Di Tommaso S; Robino L; Basso F; D'Orazio P
    Dev Biol Stand; 1997; 89():275-8. PubMed ID: 9272360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bordetella parapertussis infections.
    Mastrantonio P; Giuliano M; Stefanelli P; Sofia T; De Marzi L; Tarabini G; Quarto M; Moiraghi A
    Dev Biol Stand; 1997; 89():255-9. PubMed ID: 9272358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines.
    Canthaboo C; Williams L; Xing DK; Corbel MJ
    Vaccine; 2000 Nov; 19(6):637-43. PubMed ID: 11090715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
    Halperin SA; Eastwood B; Barreto L; Mills E; Blatter M; Reisinger K; Bader G; Keyserling H; Roberts EA; Guasparini R
    Scand J Infect Dis; 1995; 27(3):279-87. PubMed ID: 8539554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and composition of acellular pertussis vaccines. Consideration of potential effects on vaccine efficacy.
    Hewlett EL
    Dev Biol Stand; 1997; 89():143-51. PubMed ID: 9272344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents.
    Hodder SL; Cherry JD; Mortimer EA; Ford AB; Gornbein J; Papp K
    Clin Infect Dis; 2000 Jul; 31(1):7-14. PubMed ID: 10913389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of antibodies against fimbria type 3 (Fim3) is useful diagnostic assay for pertussis.
    Oguchi K; Miyata A; Kazuyama Y; Noda A; Suzuki E; Watanabe M; Nakayama T
    J Infect Chemother; 2015 Sep; 21(9):639-46. PubMed ID: 26134278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multicenter acellular pertussis trial: an overview.
    Decker MD; Edwards KM
    J Infect Dis; 1996 Nov; 174 Suppl 3():S270-5. PubMed ID: 8896528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological correlates of immunity to Bordetella pertussis.
    Hewlett EL; Halperin SA
    Vaccine; 1998 Dec; 16(20):1899-900. PubMed ID: 9796040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.